Regarding anti-AMPAR antibodies, FTD patients that carry anti-GluA3 antibodies are characterized by a reduction of both the postsynaptic expression of GluA3-containing AMPA receptors and a decreased intracortical facilitation, which predicts a more pronounced impairment of glutamatergic neurotransmission. This evidence concerns the gene GRIA3 and frontotemporal dementia.